Life Sciences Commercial Software
The buyer population — Pharmaceutical and medicine manufacturing
Base industry report for 3254 →- Establishments · CanadaA
- 428
- Under 10 employeesA
- 46%
- Establishments · USA
- 2,882
- Employment · USA
- 314,242
- Payroll · USA
- $33.4B
Of 428 Canadian establishments with employees, 46% have fewer than ten — an industry where large establishments carry real weight. Each of those is one potential account, before any filter for size or fit.
Entry signal — what decides who wins here
Structure decidesThe binding constraint is not executional. Being better than the incumbent does not, by itself, get you in — this one is cleared with capital, an asset, or a permission.
Raise or borrow the entry ticket, or buy an operator who has already paid it. The barrier is money rather than permission, so it yields to a balance sheet — and an acquisition is usually cheaper than a start.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 8
The binding constraint — entry cost
Veeva is the proof case every vertical SaaS pitch cites, and it now occupies its category completely. Validated-system requirements (GxP, 21 CFR Part 11) impose a compliance floor measured in years, not months.
Sectors joined: Biotech · Biotech/Oncology · Pharmaceutical Data · Pharmaceutical · Therapeutics · Oncology
[UNVERIFIED] Sector-to-NAICS mapping is analyst judgment — see data/angel-sector-map.json. Counts are a per-record cross-reference and are not additive across records.
The incumbent
Who owns this market and who is coming for it. Fields a screen never reached say so rather than guessing.
Financials & market size — sourced
Figures that came from a filing, a results release or reputable reporting, each carrying its evidence tier.
Market size, derived
Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.
Disclosed revenue from 1 of 5 named vendors. The market is at least this large.
No vendor has both a disclosed revenue and a published share.
Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.
Competitor set · 5 named · 1 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| Veeva SystemsNYSE: VEEVA | $3.2B | — | FY2026, FYE 31 Jan 2026, +16% |
| IQVIANYSE: IQVC | not disclosed | — | Technology & Analytics segment not isolated here |
| CertaraNASDAQ: CERTC | not disclosed | — | Listed (NASDAQ: CERT) but the regulatory and quality line is not broken out; not researched for this record |
| Medidata (Dassault)C | not disclosed | — | Not separately disclosed |
| Salesforce Life Sciences CloudC | not disclosed | — | Competes directly since Veeva's move off the Salesforce platform |
Startups & challengers
Newer and smaller vendors going at the incumbent — funded challengers first. Named, not researched to the depth of the field above; a company with a page here links to it.
| Company | Stage | What it does | Raised |
|---|---|---|---|
| AcuityMD | Funded challenger | Commercial intelligence for medtech sales teams: which surgeons and sites to target | — |
| Definitive Healthcare | Funded challenger | Healthcare provider data and commercial intelligence for life-science and health sellers | — |
| Komodo Health | Funded challenger | Healthcare claims data and analytics for life sciences commercial teams. | — |
| Veeva | Funded challenger | Cloud CRM, data and clinical software for pharma and biotech. | — |
Evidence
Evidence. Incumbent financials and market-share figures on this record ARE sourced (tier A/B, see the financials block). The cut factor and reasoning remain analyst judgment and were not tested against customers.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
Member companies ('40+' per homepage); the research-based pharmaceutical companies whose Canadian commercial and medical teams run Veeva-class systems.
Professional body for regulatory-affairs staff at Canadian pharma and device companies, the people who own validated-system and submission processes. No member count on site.
US trade association of research-based biopharmaceutical companies; policy advocacy body. No member count on homepage.
Global association for clinical, regulatory and drug-development professionals; its DIA Global Annual Meeting is where clinical and regulatory software vendors exhibit. No member count on homepage.
Members ('25,000+ in over 120 countries' per homepage); GAMP and computerised-system validation guidance comes from here. Has a Canada affiliate; 2026 Annual Meeting 18-21 Oct, National Harbor MD.
Magazine for marketing decision makers in pharma, biotech and medical devices; covers CRM, omnichannel and commercial-software vendors.
Haymarket trade title for pharma commercial and medical marketing teams; news, agency rankings and awards.
Fierce Pharma (fiercepharma.com), Life Sciences Ontario and BIOTECanada are live and adjacent but broader than the commercial-software audience. r/pharmaindustry could not be verified.
The businesses it sells to
Operating-business records filed along the same branch of NAICS — the customers of this software, screened as businesses in their own right.
No operating-business record has been written along this branch yet. The base industry report says what the subsector typically runs on.
Other software on this branch
The system of record for every adverse event a drug company hears about. Pharmacovigilance software takes in suspected adverse reactions from call centres, literature, partners, trials and social media; codes them in MedDRA and WHODrug; runs medical review; builds each Individual Case Safety Report (ICSR) in ICH E2B format and sends it to the regulators on the clock; detects signals across the case base; and assembles periodic reports (PSUR/PBRER, DSUR). How it differs from the three neighbouring 3254/5417 records: regulatory information management (RIM) tracks registrations and publishes the eCTD dossier — the application; clinical-trial data management (EDC, CTMS — Medidata, Veeva Clinical) runs the trial; life-sciences commercial software (Veeva CRM) runs the sales force. Safety runs for the whole life of the product after the first patient is dosed, and its output is a legally required report with a 15-day clock. The vendors overlap (ArisGlobal, Veeva, Ennov and EXTEDO sell both RIM and safety), so their funding is not re-told here. The regulators set the floor and just raised it. FDA's adverse-event system, renamed AEMS (formerly FAERS), requires E2B(R3) for premarket IND safety reports from 1 April 2026 and for postmarketing ICSRs sent through ESG NextGen from 1 October 2026, with E2B(R2) accepted only through 30 September 2026 [A, FDA]. EMA's EudraVigilance has required the ISO ICSR standard as implemented by ICH E2B(R3) since 30 June 2022, and electronic reporting is obligatory for marketing authorisation holders and trial sponsors [A, EMA]. Health Canada's Canada Vigilance guidance (effective 2018, clarified by a February 2026 notice) still aligns with E2B(R2), prefers electronic reporting through its Trading Partner Management Office, and sets 15 calendar days for serious domestic reactions [A, canada.ca]. Every safety database must be validated, connected to each authority's gateway and ready for inspection before it processes a single live case. Oracle Argus is the installed incumbent. Oracle's own documentation calls Argus Safety the core of Argus Standard and Enterprise editions, used to take in cases, code them, assess them and generate expedited and periodic reports; it now sells it as Safety One Argus with Safety One Intake and Empirica Signal [A, docs.oracle.com]. Oracle does not report the line, and oracle.com refuses automated access, so the installed base is UNVERIFIED — the evidence is indirect: Cognizant, which processes over 4 million case versions a year for clients, says it runs case processing on 'robust safety databases like Argus' and upgrades clients' Argus installs [C, Cognizant]. The one scale figure in the market is the one being sold. ArisGlobal (Waltham, Massachusetts; founded 1989; LifeSphere Safety) serves more than 200 enterprise customers, processes over 12 million safety cases a year and expects about $175M of 2026 revenue; Nordic Capital, owner since 2019, agreed on 23 July 2026 to sell it to Dassault Systèmes for about $1.8B in cash plus up to $200M tied to AI revenue milestones, closing expected in the second half of 2026 [A, Dassault and Nordic Capital releases]. That is roughly 10× expected revenue, and it puts ArisGlobal beside Medidata inside Dassault. Veeva Safety (intake, processing and submission, with SafetyDocs, Safety Signal and Safety Workbench) lists itself at 51–100 customers [C, veeva.com] inside Veeva's $1,748.4M R&D and Quality line (FY2026, of $3,195.3M total revenue) [A, 10-K]; Veeva's 10-K names IQVIA, Dassault Systèmes, OpenText and Oracle as its competitors in development applications. IQVIA sells the Vigilance Platform as SaaS alongside its Lifecycle Safety outsourcing [C, iqvia.com]. The second tier is private-equity owned and consolidating. Ennov (Paris; 650+ life-sciences customers across all its modules, including PV Case Management and Signal Detection) took a growth investment led by Bregal Sagemount with Ardian in May 2026, terms undisclosed [B, Goodwin]. Qinecsa (London; 1,300+ employees) was built from Commonwealth Informatics, Bioclinica's drug-safety business and MyMeds&Me and bought Denmark's Insife (HALOPV) in April 2024; it sells Reportum intake, HaloPV and Vigilance Workbench signal software alongside outsourced case work [A, company; B, Samedan]. EXTEDO's Safety Management Hub is a smaller line next to its eCTD business. Much of the spend is labour, and it flows to services firms. Cognizant says it processes over 4 million adverse-event case versions a year and has helped more than half of the top 10 pharma companies with their PV environments [C]; Accenture sells AI-driven pharmacovigilance as R&D outsourcing [C]; Genpact launched its PVAI case-processing automation in 2017 and spun PVAI out as an independent company in February 2023 [A, Genpact release; B for the spin-out]. Clarivate sells the data around the case — Drug Safety Triager for literature review and OFF-X safety intelligence [C]. The AI attack is real but already funded and already copied. Graph AI (Graph Safety) raised a $13.3M Series A led by Insight Partners with Bessemer in September 2026 for an AI-native intake, safety database and aggregate-reporting stack, and claims case turnaround cut from over three hours to under ten minutes [B for the round, C for the claim]. Every incumbent ships the same promise: Oracle Safety One Intake, ArisGlobal's NavaX generative case processing, Veeva AI in safety, IQVIA's AI-assisted processing. No Canadian vendor of note. Canadian marketing authorisation holders (Innovative Medicines Canada has 40+ member companies) buy the same global databases and file to Canada Vigilance from them. Entry cost and regulatory drag decide it: a new safety database must be validated, certified on the FDA, EMA and Health Canada gateways and survive inspection before its first live case; a sponsor moves its case history only in a multi-year validated migration; the top tier is now a $1.8B Dassault asset, a $1.75B-line Veeva product and Oracle's installed base; and the only opening — AI-native case processing — is already a venture-funded race the incumbents are matching feature for feature.
Veeva owns the top of this market, and the rest of it is being bought. Veeva RIM (Registrations, Submissions, Submissions Publishing, Submissions Archive) sits inside Veeva's R&D and Quality Solutions line, which earned $1,748.4M in FY2026 (subscription $1,426.6M plus services $321.8M, year to 31 January 2026) [A, 10-K]. Veeva does not break RIM out, and it names IQVIA, Dassault Systèmes, OpenText, Oracle and Honeywell as the vendors that compete with parts of its Development and Quality clouds [A, 10-K]. The second tier has changed hands three times in thirty months. Bertelsmann bought EXTEDO (Munich, founded 1996, eCTDmanager and the EXTEDOpulse RIM platform) in February 2024 [A, EXTEDO's own about page]. That same month Ennov (Paris), which also sells PV, quality and clinical software, bought Calyx's Enterprise Technology division, whose RIM and InSight publishing tools Ennov still sells [B, Manatt release; C, Ennov's site]. On 23 July 2026 Dassault Systèmes agreed to buy ArisGlobal (LifeSphere: RIM, submissions, labelling, safety) for about $1.8B in cash plus up to $200M in earn-outs. ArisGlobal is expected to make $175M of revenue in 2026 across safety, regulatory, quality and medical affairs, and claims 200+ customers, half of them among the top 50 biopharmas [A, Dassault release]. That deal prices a mixed safety-and-regulatory suite at roughly 10x revenue. On authoring, Certara sold its Regulatory and Medical Writing business (the old Synchrogenix) to Veristat. It was announced at up to $135M and closed on 8 May 2026. That business earned $50M of revenue and $17M of adjusted EBITDA in 2025 and had about 220 staff [A, 8-K]. The writing work there was mostly done by people, not by software. LORENZ (Frankfurt; docuBridge) claims 2,000+ paid installations in 48 countries, including 19 regulators, Health Canada and the FDA among them [C]. IQVIA sells SmartSolve RIM (launched as RIM Smart in 2019) for MedTech, IVD and pharma [C]. DXC still sells FirstDoc, FirstPoint, TRS, Writer and ToolBox [C]. The start-ups sit below all of these. Rimsys (MedTech RIM) raised a $16M Series A led by Bessemer in 2021 [A, company post]. Kivo targets clinical-stage biotech. Yseop (Paris) sells AI-written CSRs and CTD documents. Freyr mixes regulatory services with its freya fusion software. The regulators set the switching moments. FDA has accepted new applications in eCTD v4.0 since 16 September 2024 but has set no date for making it mandatory [A, fda.gov]. EMA made v4.0 optional for new centralised MAAs on 22 December 2025. It becomes strongly recommended from Q1 2027 and mandatory from Q1 2028; the forward-compatibility date for existing v3.2.2 dossiers is still pending [A, EMA eSubmission]. EMA's Product Management Service (PMS, the IDMP piece of SPOR) went live on 31 May 2024 [B, EMA guidance via search]. Health Canada's v4.0 Module 1 guide is still a draft from 2019 [A, canada.ca]. Each cutover is a reason to re-buy publishing software, and every incumbent already markets its v4.0 readiness. How it differs from its neighbours. The life-sciences commercial record is CRM and data: Veeva CRM against Salesforce. The clinical-trial record covers EDC, CTMS and eTMF. This record is the regulatory department's own system of record: what is registered where, what has been submitted, and the dossier itself. Pharmacovigilance (ArisGlobal's larger half, Ennov PV, Oracle Argus) and serialisation are separate records still to come. Incumbent vulnerability decides it. Veeva is growing and bundles RIM with its clinical and quality vaults, and three strategic buyers are absorbing the independents, so a new RIM vendor has an exit market but little open ground.
TraceLink is the network incumbent for US DSCSA data exchange, and the line-level systems are sold by packaging-equipment groups that keep consolidating. TraceLink (North Reading, Massachusetts; founded 2009) had raised $167M by its 2018 Series D, a $93M round led by Georgian Partners, and said it connected more than 270,000 drug companies, distributors, logistics providers, hospitals and pharmacies [B, MedCity News; network count C]. No later round or any revenue was found, and tracelink.com refuses automated retrieval. The other big seller is now part of a US-listed group. Antares Vision (Travagliato, Brescia) bought the assets of the liquidated French vendor Adents for about €1.5M in November 2020 [B, Pharmaceutical Commerce] and agreed to buy rfxcel for $120M in February 2021 [B]. Antares reported €90.4M of revenue in H1 2025 [B, Soldionline], across inspection and traceability, not serialisation alone. Crane NXT (NYSE: CXT) then bought Antares in stages, completing it on 31 March 2026 for about €362M in cash. It booked $98.9M of Antares backlog at that date [A, Crane NXT Q1 2026 release on SEC], and Antares was delisted from Euronext Milan. Systech now sits with Dover's Markem-Imaje (its site carries the Markem-Imaje mark [C]; the January 2020 deal pages refused retrieval). Movilitas, bought by Engineering Group in 2022, now redirects to Engineering's IndX division, which sells Movilitas.Cloud and SAP ATTP projects [C]. Tjoapack, a contract packager rather than a software vendor, is now part of Alcami [C]. Körber's PAS-X Track & Trace (March 2025 release, Lüneburg) runs on-premise, in the customer's cloud or as Körber-managed SaaS [C]. Optel (Canada, founded 1989) claims 6,000 systems installed and 25 billion products tracked a year [C]. SAP sells Advanced Track and Trace for Pharmaceuticals (ATTP) to its own ERP base. LSPedia (OneScan) claims 1,600+ companies and sells to pharmacies [C]. Axway, now part of 74Software, still sells an EPCIS repository product, Axway Track & Trace [C]. The mandate deadlines have mostly passed. DSCSA's enhanced drug distribution security requirements took effect on 27 November 2023, followed by a one-year stabilisation period. FDA's October 2024 exemptions then ran out for manufacturers and repackagers on 27 May 2025, for wholesale distributors on 27 August 2025, and for dispensers with 26 or more full-time employees on 27 November 2025 [B, Quarles summary of the FDA notice]. Small dispensers (25 or fewer pharmacists and technicians) are now exempt until 27 November 2027 [A, FDA exemptions page, content current 26 Aug 2026]. The EU's EMVS links the national systems of 29 countries to the European Hub, with 2,900+ marketing authorisation holders, 4,000+ wholesalers and 115,000+ commercial pharmacies connected [A, EMVO]. The compliance wave that funded this category is over in the EU and nearly over in the US, so the remaining buyers are mainly renewing systems they already run. The lock-in has three layers. Line-level serialisation (L1–L3) is GxP-validated equipment on packaging lines. The enterprise serial repository (L4) holds EPCIS connections to every trading partner. A network vendor like TraceLink adds partner-to-partner links on top. Replacing any layer means revalidating and re-onboarding counterparties. How it differs from its neighbours. Food safety and traceability (311) is lot-level FSMA 204 record-keeping, not unit-level serials with regulator verification. Life-sciences commercial software (Veeva CRM) and regulatory information management (RIM, submissions) handle sales and the dossier, not the pack. A warehouse management system runs the building and consumes the serial data. Incumbent vulnerability decides it: one network is entrenched, the line-level makers are now inside Crane NXT, Dover and Körber, and the last open segment (small US pharmacies, exempt to November 2027) already has LSPedia, plus wholesaler-provided tools.